Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.
O'Dell JR, Curtis JR, Mikuls TR, Cofield SS, Bridges SL, Ranganath VK, Moreland LW. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. Arthritis Rheum. 2013 Aug; 65(8):1985-94.